Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 276
- Registration Number
- NCT00005603
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- T-cell Childhood Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Radiation: radiation therapyOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 392
- Registration Number
- NCT00002700
- Locations
- 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Untreated Adult Acute Myeloid LeukemiaUntreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT00003934
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Working Group of MDS in Childhood
- Registration Number
- NCT00047268
- Locations
- 🇩🇪
Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg, Germany
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Procedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 393
- Registration Number
- NCT00004228
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3054
- Registration Number
- NCT00005945
- Locations
- 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimProcedure: allogeneic bone marrow transplantationRadiation: radiation therapyProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1929
- Registration Number
- NCT00002514
- Locations
- 🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Swedish Medical Center, Englewood, Colorado, United States
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
- Conditions
- Mixed GliomasRecurrent Brain TumorAnaplastic AstrocytomaAnaplastic OligodendrogliomaGlioblastoma Multiforme
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 35
- Registration Number
- NCT00004688
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.